Tag Archives: EASL

New triple drug combination shows promise in hepatitis C infected patients

Barcelona (Spain): New data presented on Thursday at The International Liver Congress 2016 in Barcelona, Spain, demonstrates a high sustained virologic response (SVR) at 12 weeks from the all-oral combination of sofosbuvir/velpatasvir and experimental compound GS-9857 in patients with the Hepatitis C virus (HCV).

Posted in Hepatology, RESEARCH | Tagged , , , , , , , , , , | Leave a comment